 |
Prospector
Profile
07.1094
|
| |
| Insulet Corporation |
NAICS |
325412 |
| 9 Oak Park Drive
Bedford, MA 01730 |
Description |
Pharmaceutical Products Mfg. |
| (781) 457-5000 |
Employees |
150 |
| http://www.myomnipod.com/ |
Revenue |
(mil) |
0.0020 |
| |
Income |
(mil) |
-25.0700 |
| |
Assets |
(mil) |
44.9070 |
| |
Liability |
(mil) |
135.8200 |
| |
(for the year ended 2006-09-30) |
| |
|
Category:
Loss/Deficit
|
| |
|
Event:
Insulet Corporation reported a net loss of $11,560,000 for the first quarter ended March 31, 2007, a substantial increase over the net loss reported during the first quarter of 2006 of $6,940,000. As a result of its recurring losses, the Company has an accumulated deficit of $113,600,000 and stockholder's deficit of $113,075,000 as of March 31, 2007. The Company also reported strained liquidity with $27,247,000 in total current assets available to pay $40,931,000 in total current liabilities.
|
| |
|
Intellectual Property:
As of December 31, 2006, the Company had obtained 17 issued United States patents, and had 33 additional pending U.S. patent applications. The Company is also seeking patent protection for its proprietary technology in Europe, China, Japan, India and other countries and regions throughout the world. The issued patents and pending patent applications cover the OmniPod System. On January 23, 2002, the Company entered into a development and license agreement with TheraSense, Inc., regarding the incorporation of the FreeStyle blood glucose meter in the PDM. The Company has registered the trademarks OMNIPOD and the OMNIPOD design with the U.S. Patent and Trademark Office. It has applied with the United States Patent and Trademark Office to register the trademarks INSULET and POD. [SEC Filing S-1 05-14-07]
|
| |
|
Description:
The Company engages in the development, manufacture, and marketing of insulin infusion system for people with insulin-dependent diabetes in the United States.
|
| |
|
Officers:
Duane DeSisto (Pres., CEO & Dir.); Carsten Boess (CFO); Luis Malavé (COO); R. Anthony Diehl, Esq. (Gen. Counsel); Alison de Bord (Dir.); Gary Eichhorn (Dir.); Ross Jaffe, M.D. (Dir); Charles Liamos (Dir.); Gordie Nye (Dir.); Jonathan Silverstein (Dir.); Steven Sobieski (Dir.)
|
| |
|
Auditor:
Ernst & Young LLP
|
| |
|
Securities:
Common Stock-Symbol PODD; NasdaqCM;
26,322,811 common shares outstanding as of June 22, 2007.
|
| |
| |
| |
| return to main page |
|
|
